Cargando…
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomark...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315958/ https://www.ncbi.nlm.nih.gov/pubmed/30572662 http://dx.doi.org/10.3390/cancers10120527 |
_version_ | 1783384416795492352 |
---|---|
author | Hanssen, Annkathrin Riebensahm, Carlotta Mohme, Malte Joosse, Simon A. Velthaus, Janna-Lisa Berger, Lars Arne Bernreuther, Christian Glatzel, Markus Loges, Sonja Lamszus, Katrin Westphal, Manfred Riethdorf, Sabine Pantel, Klaus Wikman, Harriet |
author_facet | Hanssen, Annkathrin Riebensahm, Carlotta Mohme, Malte Joosse, Simon A. Velthaus, Janna-Lisa Berger, Lars Arne Bernreuther, Christian Glatzel, Markus Loges, Sonja Lamszus, Katrin Westphal, Manfred Riethdorf, Sabine Pantel, Klaus Wikman, Harriet |
author_sort | Hanssen, Annkathrin |
collection | PubMed |
description | Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomarkers to differentiate oligo-metastatic patients for better risk assessment. Using the CellSearch(®) system, few CTCs were detected among NSCLC patients with brain metastases (n = 52, 12.5% ≥ two and 8.9% ≥ five CTC/7.5 mL blood) and especially oligo-metastatic brain patients (n = 34, 5.9%, and 2.9%). Still, thresholds of both ≥ two and ≥ five CTCs were independent prognostic indicators for shorter overall survival time among all of the NSCLC patients (n = 90, two CTC ≥ HR: 1.629, p = 0.024, 95% CI: 1.137–6.465 and five CTC ≥ HR: 2.846, p = 0.0304, CI: 1.104–7.339), as well as among patients with brain metastases (two CTC ≥ HR: 4.694, p = 0.004, CI: 1.650–13.354, and five CTC ≥ HR: 4.963, p = 0.003, CI: 1.752–14.061). Also, oligo-brain NSCLC metastatic patients with CTCs had a very poor prognosis (p = 0.019). Similarly, in other tumor entities, only 9.6% of patients with brain metastases (n = 52) had detectable CTCs. Our data indicate that although patients with brain metastases more seldom harbor CTCs, they are still predictive for overall survival, and CTCs might be a useful biomarker to identify oligo-metastatic NSCLC patients who might benefit from a more intense therapy. |
format | Online Article Text |
id | pubmed-6315958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63159582019-01-09 Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease Hanssen, Annkathrin Riebensahm, Carlotta Mohme, Malte Joosse, Simon A. Velthaus, Janna-Lisa Berger, Lars Arne Bernreuther, Christian Glatzel, Markus Loges, Sonja Lamszus, Katrin Westphal, Manfred Riethdorf, Sabine Pantel, Klaus Wikman, Harriet Cancers (Basel) Article Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomarkers to differentiate oligo-metastatic patients for better risk assessment. Using the CellSearch(®) system, few CTCs were detected among NSCLC patients with brain metastases (n = 52, 12.5% ≥ two and 8.9% ≥ five CTC/7.5 mL blood) and especially oligo-metastatic brain patients (n = 34, 5.9%, and 2.9%). Still, thresholds of both ≥ two and ≥ five CTCs were independent prognostic indicators for shorter overall survival time among all of the NSCLC patients (n = 90, two CTC ≥ HR: 1.629, p = 0.024, 95% CI: 1.137–6.465 and five CTC ≥ HR: 2.846, p = 0.0304, CI: 1.104–7.339), as well as among patients with brain metastases (two CTC ≥ HR: 4.694, p = 0.004, CI: 1.650–13.354, and five CTC ≥ HR: 4.963, p = 0.003, CI: 1.752–14.061). Also, oligo-brain NSCLC metastatic patients with CTCs had a very poor prognosis (p = 0.019). Similarly, in other tumor entities, only 9.6% of patients with brain metastases (n = 52) had detectable CTCs. Our data indicate that although patients with brain metastases more seldom harbor CTCs, they are still predictive for overall survival, and CTCs might be a useful biomarker to identify oligo-metastatic NSCLC patients who might benefit from a more intense therapy. MDPI 2018-12-19 /pmc/articles/PMC6315958/ /pubmed/30572662 http://dx.doi.org/10.3390/cancers10120527 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hanssen, Annkathrin Riebensahm, Carlotta Mohme, Malte Joosse, Simon A. Velthaus, Janna-Lisa Berger, Lars Arne Bernreuther, Christian Glatzel, Markus Loges, Sonja Lamszus, Katrin Westphal, Manfred Riethdorf, Sabine Pantel, Klaus Wikman, Harriet Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease |
title | Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease |
title_full | Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease |
title_fullStr | Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease |
title_full_unstemmed | Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease |
title_short | Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease |
title_sort | frequency of circulating tumor cells (ctc) in patients with brain metastases: implications as a risk assessment marker in oligo-metastatic disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315958/ https://www.ncbi.nlm.nih.gov/pubmed/30572662 http://dx.doi.org/10.3390/cancers10120527 |
work_keys_str_mv | AT hanssenannkathrin frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT riebensahmcarlotta frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT mohmemalte frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT joossesimona frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT velthausjannalisa frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT bergerlarsarne frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT bernreutherchristian frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT glatzelmarkus frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT logessonja frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT lamszuskatrin frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT westphalmanfred frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT riethdorfsabine frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT pantelklaus frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease AT wikmanharriet frequencyofcirculatingtumorcellsctcinpatientswithbrainmetastasesimplicationsasariskassessmentmarkerinoligometastaticdisease |